These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9004110)

  • 21. Aggressive challenging behaviour and intellectual disability.
    Benson BA; Brooks WT
    Curr Opin Psychiatry; 2008 Sep; 21(5):454-8. PubMed ID: 18650686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic buspirone treatment normalizes open field behavior in olfactory bulbectomized rats: assessment with a quantitative autoradiographic evaluation of the 5-HT1A binding sites.
    Sato H; Skelin I; Debonnel G; Diksic M
    Brain Res Bull; 2008 Mar; 75(5):545-55. PubMed ID: 18355630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities.
    Garber HJ; McGonigle JJ; Slomka GT; Monteverde E
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1157-60. PubMed ID: 1429420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buspirone's efficacy in organic-induced aggression.
    Stanislav SW; Fabre T; Crismon ML; Childs A
    J Clin Psychopharmacol; 1994 Apr; 14(2):126-30. PubMed ID: 8195453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy.
    Heo JH; Lee ST; Chu K; Kim M
    J Neurol Sci; 2008 Aug; 271(1-2):87-90. PubMed ID: 18466925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
    Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Modification of self-injury and self-mutilation behavior--analysis of a single case intervention study of a boy in a school for mentally retarded].
    Lauth GW; Weiss SR
    Prax Kinderpsychol Kinderpsychiatr; 2003 Feb; 52(2):109-21. PubMed ID: 12647604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence, types and characteristics of aggressive behaviour in treatment facilities for adults with mild intellectual disability and severe challenging behaviour.
    Tenneij NH; Koot HM
    J Intellect Disabil Res; 2008 Feb; 52(Pt 2):114-24. PubMed ID: 18197950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems.
    Miczek KA; Fish EW; De Bold JF; De Almeida RM
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):434-58. PubMed ID: 12373445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons.
    Ruedrich SL; Grush L; Wilson J
    Am J Ment Retard; 1990 Jul; 95(1):110-9. PubMed ID: 1974768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoxetine treatment of severe self-injury in young adults with mental retardation.
    Ricketts RW; Goza AB; Ellis CR; Singh YN; Singh NN; Cooke JC
    J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):865-9. PubMed ID: 8340311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ataxia from lithium toxicity successfully treated with high-dose buspirone: a single-case experimental design.
    Megna J; O'dell M
    Arch Phys Med Rehabil; 2001 Aug; 82(8):1145-8. PubMed ID: 11494197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.
    Navinés R; Martín-Santos R; Gómez-Gil E; Martínez de Osaba MJ; Imaz ML; Gastó C
    Psychoneuroendocrinology; 2007 May; 32(4):411-6. PubMed ID: 17337123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Buspirone in the treatment of cerebellar ataxia].
    Svetel M; Vojvodić N; Filipović SR; Dragasević N; Sternić N; Kostić VS
    Srp Arh Celok Lek; 1999; 127(9-10):312-5. PubMed ID: 10649900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maladaptive behaviors associated with neuroleptic drug maintenance.
    Chadsey-Rusch J; Sprague RL
    Am J Ment Retard; 1989 May; 93(6):607-17. PubMed ID: 2566315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of spinocerebellar ataxia with buspirone.
    Assadi M; Campellone JV; Janson CG; Veloski JJ; Schwartzman RJ; Leone P
    J Neurol Sci; 2007 Sep; 260(1-2):143-6. PubMed ID: 17512011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic buspirone treatment normalizes regional serotonin synthesis in the olfactory bulbectomized rat brain: an autoradiographic study.
    Watanabe A; Hasegawa S; Nishi K; Nguyen KQ; Diksic M
    Brain Res Bull; 2006 Mar; 69(2):101-8. PubMed ID: 16533657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lithium and aggression in adults].
    Thibaut F; Colonna L
    Encephale; 1992; 18(2):193-8. PubMed ID: 1639003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidepressant-like effects of 5-hydroxytryptamine1A receptor agonists on operant responding under a response duration differentiation schedule.
    Kinney GG; Griffith JC; Hudzik TJ
    Behav Pharmacol; 1998 Jul; 9(4):309-18. PubMed ID: 10065919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.